Introduction and Objectives
To evaluate the effectiveness and the safety of the transurethral bipolar vaporization (TUV-P.is) in the treatment of benign prostate hyperplasia (B.P.H).
Material and Methods
From July 2008 to May 2009, 91 patients with B.P.H and prostate volume less then 50 cc, underwent TUV-P.is using the OLYMPUS (TUR-plasma vaporization) device. Patients with prostate volume more then 50 cc, prostate cancer, urethral strictures and neurogenous bladder were excluded. We have also evaluate pre- & postoperatively, the grade of urinary discomfort due the B.P.H, (using the IPSS questionnaire and the QoL score), the residual urine volume, the prostate volume, the Q max, the value of Hct, the operative time and the duration of permanence of intravescical catheter.
Postoperatively non-one of our patients had haematuria, retention of urine or urethral strictures. Mean resection time was 31 min. (10–59), mean duration of permanence of intravescical catheter was 1.6 days (1 to 5).The mean postoperative Qmax. rate after 2 months was 17.2 ml/sec in confront of those preoperative that was 8.4 ml/sec. Two months postoperatively the IPSS was diminished from 20 (preoperative) to 7 (postoperative), such as the QoL score from 4.8 to 1.5 correspondently. There was also a diminution in the mean residual urine volume from 88 ml to 17 ml in the same period of time. Moreover preoperative and postoperative levels of serum hematocrit were not statistically different.
From our initial results from the use of Transurethral Plasma vaporization in saline (TUV-P.is), it seems that it is a valid, secure and efficacy technique for the treatment of B.P.H. Furthermore studies and a longer follow-up period is needed in order to have more validated results for this therapeutic approach.
© 2009 European Association of Urology. Published by Elsevier Inc. All rights reserved.